AstraZeneca Stock Forecast, Price & News

AstraZeneca's stock was trading at $44.58 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, AZN shares have increased by 26.6% and is now trading at $56.45.
View which stocks have been most impacted by COVID-19.

10 Wall Street analysts have issued "buy," "hold," and "sell" ratings for AstraZeneca in the last year. There are currently 3 sell ratings, 2 hold ratings and 5 buy ratings for the stock, resulting in a consensus recommendation of "Hold."
View analyst ratings for AstraZeneca.

AstraZeneca is scheduled to release its next quarterly earnings announcement on Thursday, October 22nd 2020.
View our earnings forecast for AstraZeneca.

AstraZeneca plc (NYSE:AZN) announced its earnings results on Thursday, July, 30th. The company reported $0.48 earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of $0.44 by $0.04. The firm had revenue of $6.28 billion for the quarter, compared to analyst estimates of $6.27 billion. AstraZeneca had a return on equity of 37.72% and a net margin of 8.36%. The company's quarterly revenue was up 9.7% compared to the same quarter last year. During the same period in the previous year, the company posted $0.73 earnings per share.
View AstraZeneca's earnings history.

AstraZeneca declared a semi-annual dividend on Friday, July 31st. Investors of record on Friday, August 14th will be given a dividend of $0.45 per share on Monday, September 14th. This represents a dividend yield of 2.5%. The ex-dividend date is Thursday, August 13th.
View AstraZeneca's dividend history.

AstraZeneca shares split on Monday, July 27th 2015. The 2-1 split was announced on Friday, June 26th 2015. The newly issued shares were issued to shareholders after the market closes on Friday, July 24th 2015. An investor that had 100 shares of AstraZeneca stock prior to the split would have 200 shares after the split.

10 analysts have issued 12 month target prices for AstraZeneca's shares. Their forecasts range from $60.00 to $65.00. On average, they expect AstraZeneca's share price to reach $61.67 in the next twelve months. This suggests a possible upside of 9.2% from the stock's current price.
View analysts' price targets for AstraZeneca.

Headlines about AZN stock have been trending somewhat negative on Saturday, InfoTrie Sentiment reports. The research firm identifies positive and negative media coverage by analyzing more than six thousand news and blog sources. The firm ranks coverage of publicly-traded companies on a scale of negative five to positive five, with scores nearest to five being the most favorable. AstraZeneca earned a daily sentiment score of -1.6 on InfoTrie's scale. They also gave news stories about the company a news buzz of 0.0 out of 10, meaning that recent media coverage is extremely unlikely to have an impact on the stock's share price in the next few days.
View the latest news about AstraZeneca.

AstraZeneca saw a decline in short interest in August. As of August 31st, there was short interest totaling 4,130,000 shares, a decline of 37.2% from the August 15th total of 6,580,000 shares. Based on an average daily volume of 6,690,000 shares, the days-to-cover ratio is currently 0.6 days.
View AstraZeneca's Short Interest.

Some companies that are related to AstraZeneca include Johnson & Johnson (JNJ), Roche Holdings AG Basel (RHHBY), Merck & Co., Inc. (MRK), Novartis (NVS), Pfizer (PFE), Abbott Laboratories (ABT), Novo Nordisk A/S (NVO), AbbVie (ABBV), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), Sanofi (SNY), GlaxoSmithKline (GSK), Commonwealth Bank of Australia (CSLLY), Celgene (CELG) and Zoetis (ZTS).
View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other AstraZeneca investors own include Pfizer (PFE), Gilead Sciences (GILD), Johnson & Johnson (JNJ), NVIDIA (NVDA), Moderna (MRNA), AbbVie (ABBV), Tesla (TSLA), AT&T (T), Advanced Micro Devices (AMD) and Alibaba Group (BABA).

AstraZeneca trades on the New York Stock Exchange (NYSE) under the ticker symbol "AZN."

AstraZeneca's stock is owned by a number of retail and institutional investors. Top institutional shareholders include FMR LLC (1.82%), Jennison Associates LLC (1.49%), Fisher Asset Management LLC (0.64%), GQG Partners LLC (0.35%), Bank of America Corp DE (0.32%) and Winslow Capital Management LLC (0.23%).
View institutional ownership trends for AstraZeneca.

AZN stock was sold by a variety of institutional investors in the last quarter, including CIBC Private Wealth Group LLC, FMR LLC, Winslow Capital Management LLC, Assetmark Inc., Cidel Asset Management Inc., Russell Investments Group Ltd., Charles Schwab Investment Management Inc., and Hardman Johnston Global Advisors LLC.
View insider buying and selling activity for AstraZeneca.

AZN stock was bought by a variety of institutional investors in the last quarter, including GQG Partners LLC, Two Sigma Advisers LP, Stifel Financial Corp, Fisher Asset Management LLC, Jennison Associates LLC, Avidity Partners Management LP, Nuveen Asset Management LLC, and Bank of America Corp DE.
View insider buying and selling activity for AstraZeneca.

Shares of AZN can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AZN stock can currently be purchased for approximately $56.45.

AstraZeneca has a market capitalization of $148.15 billion and generates $24.38 billion in revenue each year. The company earns $1.34 billion in net income (profit) each year or $1.75 on an earnings per share basis. AstraZeneca employs 70,600 workers across the globe.

The official website for AstraZeneca is www.astrazeneca.com.

AstraZeneca's mailing address is 1 FRANCIS CRICK AVENUE CAMBRIDGE BIOMEDICAL CAMPUS, CAMBRIDGE X0, CB2 0AA. The company can be reached via phone at 44-20-3749-5000 or via email at [email protected]